Insider Transactions in Q1 2023 at Travere Therapeutics, Inc. (TVTX)
Insider Transaction List (Q1 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 02
2023
|
Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
360
-0.83%
|
$7,920
$22.42 P/Share
|
|
Feb 01
2023
|
Elizabeth E Reed SVP, GC & CORPORATE SECRETARY |
SELL
Open market or private sale
|
Direct |
2,590
-4.31%
|
$56,980
$22.25 P/Share
|
|
Feb 01
2023
|
Peter Heerma CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,779
-2.12%
|
$37,359
$21.75 P/Share
|
|
Feb 01
2023
|
William E. Rote SENIOR VICE PRESIDENT, R&D |
SELL
Open market or private sale
|
Direct |
2,590
-4.14%
|
$56,980
$22.25 P/Share
|
|
Feb 01
2023
|
Christopher R. Cline CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,588
-2.99%
|
$33,348
$21.75 P/Share
|
|
Feb 01
2023
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
8,196
-3.34%
|
$180,312
$22.25 P/Share
|
|
Feb 01
2023
|
Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
1,671
-3.73%
|
$35,091
$21.75 P/Share
|
|
Jan 31
2023
|
Elizabeth E Reed SVP, GC & CORPORATE SECRETARY |
BUY
Grant, award, or other acquisition
|
Direct |
20,250
+25.23%
|
-
|
|
Jan 31
2023
|
Peter Heerma CHIEF COMMERCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
20,250
+19.45%
|
-
|
|
Jan 31
2023
|
William E. Rote SENIOR VICE PRESIDENT, R&D |
BUY
Grant, award, or other acquisition
|
Direct |
20,250
+24.43%
|
-
|
|
Jan 31
2023
|
Jula Inrig CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
20,250
+34.91%
|
-
|
|
Jan 31
2023
|
Christopher R. Cline CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
20,250
+27.6%
|
-
|
|
Jan 31
2023
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
97,500
+28.44%
|
-
|
|
Jan 31
2023
|
Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+18.24%
|
-
|
|
Jan 25
2023
|
Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
192
-0.55%
|
$4,032
$21.63 P/Share
|
|
Jan 24
2023
|
Peter Heerma CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,550
-2.38%
|
$32,550
$21.9 P/Share
|
|
Jan 24
2023
|
Christopher R. Cline CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
852
-2.53%
|
$17,892
$21.9 P/Share
|
|
Jan 24
2023
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
6,442
-4.18%
|
$135,282
$21.5 P/Share
|
|
Jan 24
2023
|
Elizabeth E Reed SVP, GC & CORPORATE SECRETARY |
SELL
Open market or private sale
|
Direct |
2,062
-4.93%
|
$43,302
$21.5 P/Share
|
|
Jan 24
2023
|
William E. Rote SENIOR VICE PRESIDENT, R&D |
SELL
Open market or private sale
|
Direct |
2,062
-4.64%
|
$43,302
$21.5 P/Share
|
|
Jan 24
2023
|
Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
905
-2.52%
|
$19,005
$21.9 P/Share
|
|
Jan 05
2023
|
Jula Inrig CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
442
-2.46%
|
$8,840
$20.75 P/Share
|
|
Jan 05
2023
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
5,625
-3.52%
|
$112,500
$20.75 P/Share
|
|
Jan 04
2023
|
Jula Inrig CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,051
-10.26%
|
$41,020
$20.75 P/Share
|